Tallon Kerry Patrick Makes New $37,000 Investment in Cardlytics, Inc. (NASDAQ:CDLX)

Tallon Kerry Patrick bought a new position in Cardlytics, Inc. (NASDAQ:CDLX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $37,000.

Several other institutional investors and hedge funds have also bought and sold shares of CDLX. RBF Capital LLC boosted its position in Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after purchasing an additional 369,620 shares during the last quarter. GSA Capital Partners LLP boosted its position in Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares during the last quarter. Renaissance Technologies LLC boosted its position in Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Cardlytics by 56.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company’s stock worth $1,016,000 after purchasing an additional 113,966 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after purchasing an additional 73,484 shares during the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cardlytics

In related news, CFO Alexis Desieno sold 25,118 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. The trade was a 17.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,007 shares of company stock worth $251,297 in the last quarter. 4.40% of the stock is owned by company insiders.

Cardlytics Stock Performance

NASDAQ CDLX opened at $3.06 on Friday. The company has a market cap of $155.52 million, a P/E ratio of -0.50 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The business’s 50 day moving average price is $3.72 and its 200-day moving average price is $4.58. Cardlytics, Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.18. The firm had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.26) EPS. Sell-side analysts predict that Cardlytics, Inc. will post -1.52 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on CDLX shares. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Finally, Evercore ISI started coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.